634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1 mutated advanced myeloproliferative neoplasms

A phase I study of the combination of ruxolitinib and the ERK1 2 inhibitor ulixertinib in previously treated myelofibrosis patients

Impact of essential thrombocythemia on in hospital outcomes and thrombotic complications in patients hospitalized with COVID 19 A national inpatient sample analysis 2016–2022

Dose intensive regimen of CK0804 tregs in myelofibrosis

Clinical features and outcomes of myelofibrosis patients with MPL mutations

An independent multi center analysis of the post approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Multi endpoint AI morphology model MEAM enhances risk prediction for vascular events and disease progression in MPNs

Clinical significance of earlier CHR achievement and long term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa 2b

Digital PCR based dynamic monitoring of JAK2V617F burden A decade long study unravels its prognostic value in MPN treatment response

Aspirin therapy in myelofibrosis Real world clinical practice and outcomes in 215 consecutive patients

Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real world therapy based on mutation adjusted risk score MARS stratification

Real world temporal evaluation of static risk prediction in polycythemia vera

Cytokine profiling identifies an IL‑8 IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms MPN associated with high symptom burden and poor outcomes

Exploratory risk score incorporating donor type MF HCT high risk mutations and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Competing risk model of relapse versus non relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Bone marrow adipocytes BMA as a novel biomarker of molecular response in patients with essential thrombocythemia ET and polycythemia vera PV treated with pegylated interferon alfa 2A

A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK inhibitor treatment – fraction Study IKF051 gsg MPN 006

Comprehensive analyses of patient reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Should dermatologic examinations become routine standard of care in patients with polycythemia vera Observations from the phase 3 VERIFY study prior to rusfertide exposure

Combined KIT D816V and HαT blood testing Development and validation of a targeted non invasive work up to guide invasive testing for systemic mastocytosis

Long term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia Post hoc analyses of the simplify 1 and momentum trials

Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia An exposure response and time to event analysis

Survival outcomes in ruxolitinib treated patients with myelofibrosis following crossover to momelotinib Application of the response to ruxolitinib at 6 months RR6 prognostic model to SIMPLIFY 1

Diagnostic evolution in systemic mastocytosis Clinical impact of who 2022 criteria on smoldering systemic mastocytosis identification in pioneer

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib The my PAC study

Incidence prevalence and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Achieving JAK2V617F vaf

INCB057643 a bromodomain and extra terminal protein inhibitor in combination with ruxolitinib in patients with myelofibrosis A phase 1 study of safety and efficacy

An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study

Ropeginterferon alfa 2b in 248 patients with polycythemia vera Results from the italian cohort of a prospective non interventional post authorization study ROPEG PV

Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms

MPN Myeloproliferative Neoplasm journal A platform developed by MPN patients for MPN patients to track their disease aid communication with healthcare team and create a dataset for patient data analytics